People: Developer Of Recombinant BCG Vaccine Wins Infectious Disease Research Award

Barry R. Bloom, an immunologist at the Albert Einstein College of Medicine in New York and an investigator with the Howard Hughes Medical Institute, last month received the first annual Bristol- Myers Squibb Award for Distinguished Achievement in Infectious Disease Research. The $50,000 cash prize was given in recognition of Bloom's contributions to immunology, including the development of an experimental recombinant multiple vaccine and investigations of leprosy and tuberculosis. Throughout

Written byRebecca Andrews
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Throughout most of his career, Bloom's research has focused on health problems in developing countries. But this was not always the case. "I started out revolted by applied science," recalls Bloom. "I was going to be the most basic" of basic researchers. He changed his mind about the value of applied research on a trip to India in 1968, where, he says, "I gained perspective on the world, and what my training in medical research could do."

One aspect of this focus is the development of a multipurpose vaccine created by genetically engineering the bacillus BCG (bacille Calmette-Gurin). BCG, used to protect against tuberculosis, is the oldest and most widely used vaccine in the world. Bloom's lab, along with collaborators at the University of Pittsburgh and MedImmune Inc. of Gaithersburg, Md., have developed a method of introducing protective antigens for a variety of diseases into BCG, so that this vaccine ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies